

James Lomas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3582422/publications.pdf>

Version: 2024-02-01

34
papers

916
citations

566801

15
h-index

500791

28
g-index

36
all docs

36
docs citations

36
times ranked

1219
citing authors

#	ARTICLE	IF	CITATIONS
1	Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countries. <i>Health Policy and Planning</i> , 2022, 37, 45-54.	1.0	8
2	Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates. <i>Pharmacoeconomics</i> , 2022, 40, 31-43.	1.7	16
3	The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS. <i>Pharmacoeconomics</i> , 2022, 40, 233-239.	1.7	4
4	How Responsive is Mortality to Locally Administered Healthcare Expenditure? Estimates for England for 2014/15. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 557-572.	1.0	5
5	Health Inequalities: To What Extent are Decision-Makers and Economic Evaluations on the Same Page? An English Case Study. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 793-802.	1.0	3
6	Valuing health outcomes: developing better defaults based on health opportunity costs. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 729-736.	0.7	16
7	A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States. <i>Annals of Internal Medicine</i> , 2021, 174, 25-32.	2.0	103
8	Does public long-term care expenditure improve care-related quality of life of service users in England?. <i>Health Economics (United Kingdom)</i> , 2021, 30, 2561-2581.	0.8	5
9	How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 885-903.	1.0	16
10	Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment. <i>Applied Health Economics and Health Policy</i> , 2021, , 1.	1.0	10
11	Causal impact of social care, public health and healthcare expenditure on mortality in England: cross-sectional evidence for 2013/2014. <i>BMJ Open</i> , 2021, 11, e046417.	0.8	11
12	Cured Today, Ill Tomorrow: A Method for Including Future Unrelated Medical Costs in Economic Evaluation in England and Wales. <i>Value in Health</i> , 2020, 23, 1027-1033.	0.1	10
13	Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries. <i>BMJ Global Health</i> , 2020, 5, e003006.	2.0	14
14	Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach. <i>Pharmacoeconomics</i> , 2020, 38, 1319-1331.	1.7	48
15	Assessing the Impact of Health Care Expenditures on Mortality Using Cross-Country Data. <i>World Scientific Series in Global Healthcare Economics and Public Policy</i> , 2020, , 3-49.	0.1	3
16	Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations. <i>Pharmacoeconomics</i> , 2020, 38, 665-681.	1.7	9
17	Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research. <i>Clinical Therapeutics</i> , 2020, 42, 44-59.e2.	1.1	16
18	Is an ounce of prevention worth a pound of cure? A cross-sectional study of the impact of English public health grant on mortality and morbidity. <i>BMJ Open</i> , 2020, 10, e036411.	0.8	28

#	ARTICLE	IF	CITATIONS
19	Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment. <i>Value in Health</i> , 2019, 22, 898-905.	0.1	21
20	Estimating the Marginal Productivity of the English National Health Service From 2003 to 2012. <i>Value in Health</i> , 2019, 22, 995-1002.	0.1	45
21	Accounting for Timing when Assessing Health-Related Policies. <i>Journal of Benefit-Cost Analysis</i> , 2019, 10, 73-105.	0.6	17
22	An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , 2019, 37, 631-643.	1.7	33
23	Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease. <i>Pharmacoeconomics - Open</i> , 2018, 2, 403-413.	0.9	7
24	The impact of NHS expenditure on health outcomes in England: Alternative approaches to identification in all-cause and disease specific models of mortality. <i>Health Economics (United Kingdom)</i> , 2018, 32, 1011-1037.	0.1	53
25	Resolving the "Cost-Effective but Unaffordable" Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget Impacts. <i>Value in Health</i> , 2018, 21, 266-275.	0.1	58
26	Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. <i>BMJ Global Health</i> , 2018, 3, e000964.	2.0	181
27	Economic Evaluation of Environmental Interventions: Reflections on Methodological Challenges and Developments. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 2459.	1.2	12
28	Using Mobile Health Gamification to Facilitate Cognitive Behavioral Therapy Skills Practice in Child Anxiety Treatment: Open Clinical Trial. <i>JMIR Serious Games</i> , 2018, 6, e9.	1.7	65
29	A Quasi-Monte-Carlo Comparison of Parametric and Semiparametric Regression Methods for Heavy-tailed and Non-normal Data: an Application to Healthcare Costs. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2016, 179, 951-974.	0.6	25
30	A pharmaco-economic approach to assessing the costs and benefits of air quality interventions that improve health: a case study. <i>BMJ Open</i> , 2016, 6, e010686.	0.8	12
31	The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence. <i>Pharmacoeconomics</i> , 2016, 34, 901-912.	1.7	7
32	Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence. <i>Pharmacoeconomics</i> , 2016, 34, 981-992.	1.7	4
33	Healthcare Cost Regressions: Going Beyond the Mean to Estimate the Full Distribution. <i>Health Economics (United Kingdom)</i> , 2015, 24, 1192-1212.	0.8	52
34	APPLYING BETA-TYPE SIZE DISTRIBUTIONS TO HEALTHCARE COST REGRESSIONS. <i>Journal of Applied Econometrics</i> , 2014, 29, 649-670.	1.3	27